Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:ASND OTCMKTS:EVTCY NASDAQ:MRTX NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$72.29-2.7%$77.62$14.30▼$87.83$10.18B1.262.47 million shs709,998 shsASNDAscendis Pharma A/S$255.61-2.1%$242.89$160.86▼$282.15$15.96B0.37711,265 shs138,234 shsEVTCYEvotec$1.96-0.5%$2.77$14.22▼$26.57$647.23M0.982,407 shs28,656 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AUTHRUnited Therapeutics$531.64-0.8%$552.38$272.12▼$609.35$22.57B0.58485,881 shs92,390 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%-2.75%-9.19%+7.29%+343.32%ASNDAscendis Pharma A/S0.00%-3.49%+13.07%+6.37%+53.62%EVTCYEvotec0.00%-29.62%-23.44%-39.88%-53.99%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%UTHRUnited Therapeutics0.00%-2.08%-0.17%-6.59%+83.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$72.29-2.7%$77.62$14.30▼$87.83$10.18B1.262.47 million shs709,998 shsASNDAscendis Pharma A/S$255.61-2.1%$242.89$160.86▼$282.15$15.96B0.37711,265 shs138,234 shsEVTCYEvotec$1.96-0.5%$2.77$14.22▼$26.57$647.23M0.982,407 shs28,656 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AUTHRUnited Therapeutics$531.64-0.8%$552.38$272.12▼$609.35$22.57B0.58485,881 shs92,390 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%-2.75%-9.19%+7.29%+343.32%ASNDAscendis Pharma A/S0.00%-3.49%+13.07%+6.37%+53.62%EVTCYEvotec0.00%-29.62%-23.44%-39.88%-53.99%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%UTHRUnited Therapeutics0.00%-2.08%-0.17%-6.59%+83.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.71Moderate Buy$88.7522.77% UpsideASNDAscendis Pharma A/S 3.05Buy$295.6715.67% UpsideEVTCYEvotec 0.00N/AN/AN/AMRTXMirati Therapeutics 0.00N/AN/AN/AUTHRUnited Therapeutics 2.83Moderate Buy$644.8221.29% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, MRTX, EVTCY, ASND, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ARWRArrowhead Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$88.00 ➝ $95.007/15/2026ASNDAscendis Pharma A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C)7/14/2026ARWRArrowhead Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$98.007/10/2026UTHRUnited Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$620.00 ➝ $613.007/7/2026ASNDAscendis Pharma A/S Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $280.007/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$701.00 ➝ $704.007/1/2026ARWRArrowhead Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.006/30/2026ARWRArrowhead Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/17/2026ARWRArrowhead Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$61.00 ➝ $72.006/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M12.28$0.12 per share622.28$3.64 per share19.86ASNDAscendis Pharma A/S$814.57M19.57N/AN/A($2.97) per share-86.06EVTCYEvotec$572.16M1.13$0.02 per share105.53$2.52 per share0.78MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39UTHRUnited Therapeutics$3.18B7.09$32.74 per share16.24$164.81 per share3.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6729.5121.05N/A57.87%N/A-8.37%8/6/2026 (Estimated)EVTCYEvotec$7.14M$0.414.78N/AN/A20.85%16.02%7.81%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AUTHRUnited Therapeutics$1.33B$27.0919.6316.821.7940.62%19.24%17.25%7/29/2026 (Estimated)Latest UTHR, MRTX, EVTCY, ASND, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q3 2026ARWRArrowhead Pharmaceuticals-$1.19N/AN/AN/A$47.89 millionN/A8/6/2026Q2 2026ASNDAscendis Pharma A/S$1.27N/AN/AN/A$438.69 millionN/A7/29/2026Q2 2026UTHRUnited Therapeutics$7.07N/AN/AN/A$805.22 millionN/A5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23ASNDAscendis Pharma A/S0.791.000.72EVTCYEvotec0.532.572.50MRTXMirati TherapeuticsN/A7.547.40UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/AEVTCYEvotecN/AMRTXMirati TherapeuticsN/AUTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%ASNDAscendis Pharma A/S40.00%EVTCYEvotecN/AMRTXMirati Therapeutics3.26%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableMRTXMirati Therapeutics58770.15 million67.86 millionNo DataUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableUTHR, MRTX, EVTCY, ASND, and ARWR HeadlinesRecent News About These CompaniesHsbc Holdings PLC Decreases Stock Holdings in United Therapeutics Corporation $UTHRJuly 20 at 4:47 AM | marketbeat.comBank of New York Mellon Corp Trims Holdings in United Therapeutics Corporation $UTHRJuly 19 at 3:19 AM | marketbeat.comAurora Investment Counsel Cuts Stake in United Therapeutics Corporation $UTHRJuly 19 at 3:19 AM | marketbeat.comPrincipal Financial Group Inc. Acquires 3,534 Shares of United Therapeutics Corporation $UTHRJuly 18 at 5:03 AM | marketbeat.comDorsey Wright & Associates Acquires 5,839 Shares of United Therapeutics Corporation $UTHRJuly 18 at 4:24 AM | marketbeat.comAllspring Global Investments Holdings LLC Grows Stock Holdings in United Therapeutics Corporation $UTHRJuly 18 at 3:06 AM | marketbeat.comIllinois Municipal Retirement Fund Acquires 2,401 Shares of United Therapeutics Corporation $UTHRJuly 17 at 5:35 AM | marketbeat.comFinancial Comparison: IPSEN (OTCMKTS:IPSEY) & United Therapeutics (NASDAQ:UTHR)July 17 at 5:25 AM | americanbankingnews.comAware Super Pty Ltd as trustee of Aware Super Acquires Shares of 72,530 United Therapeutics Corporation $UTHRJuly 17 at 3:12 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Assetmark Inc.July 17 at 3:11 AM | marketbeat.comMartine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) StockJuly 16, 2026 | americanbankingnews.comLivforsakringsbolaget Skandia Omsesidigt Has $18.32 Million Stock Position in United Therapeutics Corporation $UTHRJuly 15, 2026 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 SharesJuly 14, 2026 | marketbeat.comTeachers Retirement System of The State of Kentucky Grows Stock Holdings in United Therapeutics Corporation $UTHRJuly 14, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 SharesJuly 13, 2026 | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $52.56 Million Stock Holdings in United Therapeutics Corporation $UTHRJuly 13, 2026 | marketbeat.comUnited Therapeutics (UTHR) Stock Looks Cheap On Fair Value Despite Strong ReturnsJuly 12, 2026 | finance.yahoo.comFifth Third Bancorp Raises Stock Holdings in United Therapeutics Corporation $UTHRJuly 12, 2026 | marketbeat.comUnited Therapeutics (UTHR) Following FDA Approval Is The Stock Fully ValuedJuly 11, 2026 | finance.yahoo.comBank of America Securities Reaffirms Their Hold Rating on United Therapeutics (UTHR)July 11, 2026 | theglobeandmail.comJan Malcolm Sells 325 Shares of United Therapeutics (NASDAQ:UTHR) StockJuly 11, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, MRTX, EVTCY, ASND, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$72.29 -2.01 (-2.71%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$255.61 -5.39 (-2.07%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Evotec OTCMKTS:EVTCY$1.96 -0.01 (-0.51%) As of 07/17/2026Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$531.64 -4.04 (-0.75%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet MarketBeat Week in Review – 07/13- 07/17 3 Nuclear Stocks for Investors Willing to Wait Out the Dip Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Bank Earnings Are Roaring, But Wall Street Isn't Ready to Celebrate The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
